Oral Biomedicine ›› 2021, Vol. 12 ›› Issue (1): 58-61.
Previous Articles Next Articles
#br#
Received:2020-10-14
Revised:2021-02-10
Online:2021-03-25
Published:2021-04-01
CLC Number:
Jun QIAN. PPARs agonists for the treatment of osteoporosis[J]. Oral Biomedicine, 2021, 12(1): 58-61.
Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks
| [1] | [参考文献] |
| [2] | Mirza A Z, Althagafi I I, Shamshad H.Role of PPAR receptor in different diseases and their ligands: Physiological importance and clinical implications[J].Eur J Med Chem, 2019, 166:502-513 |
| [3] | Capelli D, Cerchia C, Montanari R, et al.Structural basis for PPAR partial or full activation revealed by a novel ligand binding mode[J].Sci Rep, 2016, 6:34792- |
| [4] | Dubois V, Eeckhoute J, Lefebvre P, et al.Distinct but complementary contributions of PPAR isotypes to energy homeostasis[J].J Clin Invest, 2017, 127(4):1202-1214 |
| [5] | Botta M, Audano M, Sahebkar A, et al.PPAR Agonists and Metabolic Syndrome: An Established Role?[J]. Int J Mol Sci, 2018, 19(4). |
| [6] | Papatheodorou K, Banach M, Bekiari E, et al.Complications of Diabetes 2017[J].J Diabetes Res, 2018, 2018:3086167- |
| [7] | Ensrud K E, Crandall C J.Osteoporosis[J].Ann Intern Med, 2017, 167(3):C17-C32 |
| [8] | Kersten S, Desvergne B, Wahli W.Roles of PPARs in health and disease[J].Nature, 2000, 405(6785):421-424 |
| [9] | Lee H Y, Gao X, Barrasa M I, et al.PPAR-alpha and glucocorticoid receptor synergize to promote erythroid progenitor self-renewal[J].Nature, 2015, 522(7557):474-477 |
| [10] | Bougarne N, Weyers B, Desmet S J, et al.Molecular Actions of PPARalpha in Lipid Metabolism and Inflammation[J].Endocr Rev, 2018, 39(5):760-802 |
| [11] | Huang M S, Lu J, Ivanov Y, et al.Hyperlipidemia impairs osteoanabolic effects of PTH[J].J Bone Miner Res, 2008, 23(10):1672-1679 |
| [12] | Kim Y H, Jang W G, Oh S H, et al.Fenofibrate induces PPARalpha and BMP2 expression to stimulate osteoblast differentiation[J].Biochem Biophys Res Commun, 2019, 520(2):459-465 |
| [13] | Stunes A K, Westbroek I, Gustafsson B I, et al.The peroxisome proliferator-activated receptor (PPAR) alpha agonist fenofibrate maintains bone mass,while the PPAR gamma agonist pioglitazone exaggerates bone loss,in ovariectomized rats[J].BMC Endocr Disord, 2011, 11:11- |
| [14] | Mosti M P, Ericsson M, Erben R G, et al.The PPARalpha Agonist Fenofibrate Improves the Musculoskeletal Effects of Exercise in Ovariectomized Rats[J].Endocrinology, 2016, 157(10):3924-3934 |
| [15] | Pang M, de la Monte S M, Longato L, et al.PPARdelta agonist attenuates alcohol-induced hepatic insulin resistance and improves liver injury and repair[J].J Hepatol, 2009, 50(6):1192-1201 |
| [16] | Neels J G, Grimaldi P A.Physiological functions of peroxisome proliferator-activated receptor beta[J].Physiol Rev, 2014, 94(3):795-858 |
| [17] | Schug T T, Berry D C, Shaw N S, et al.Opposing effects of retinoic acid on cell growth result from alternate activation of two different nuclear receptors[J].Cell, 2007, 129(4):723-733 |
| [18] | Magadum A, Ding Y, He L, et al.Live cell screening platform identifies PPARdelta as a regulator of cardiomyocyte proliferation and cardiac repair[J].Cell Res, 2017, 27(8):1002-1019 |
| [19] | Maltarollo V G, Kronenberger T, Windshugel B, et al.Advances and Challenges in Drug Design of PPARdelta Ligands[J].Curr Drug Targets, 2018, 19(2):144-154 |
| [20] | Scholtysek C, Katzenbeisser J, Fu H, et al.PPARbetadelta governs Wnt signaling and bone turnover[J].Nat Med, 2013, 19(5):608-613 |
| [21] | Mosti M P, Stunes A K, Ericsson M, et al.Effects of the peroxisome proliferator-activated receptor (PPAR)-delta agonist GW501516 on bone and muscle in ovariectomized rats[J].Endocrinology, 2014, 155(6):2178-2189 |
| [22] | Qian G, Fan W, Ahlemeyer B, et al.Peroxisomes in Different Skeletal Cell Types during Intramembranous and Endochondral Ossification and Their Regulation during Osteoblast Differentiation by Distinct Peroxisome Proliferator-Activated Receptors[J].PLoS One, 2015, 10(12):e143439- |
| [23] | Shafi S, Gupta P, Khatik G L, et al.PPARgamma: Potential Therapeutic Target for Ailments Beyond Diabetes and its Natural Agonism[J].Curr Drug Targets, 2019, 20(12):1281-1294 |
| [24] | Wan Y.PPARgamma in bone homeostasis[J].Trends Endocrinol Metab, 2010, 21(12):722-728 |
| [25] | Brun J, Berthou F, Trajkovski M, et al.Bone Regulates Browning and Energy Metabolism Through Mature OsteoblastOsteocyte PPARgamma Expression[J].Diabetes, 2017, 66(10):2541-2554 |
| [26] | Lu W, Wang W, Wang S, et al.Rosiglitazone Promotes Bone Marrow Adipogenesis to Impair Myelopoiesis under Stress[J].PLoS One, 2016, 11(2):e149543- |
| [27] | Marciano D P, Kuruvilla D S, Boregowda S V, et al.Pharmacological repression of PPARgamma promotes osteogenesis[J].Nat Commun, 2015, 6:7443- |
| [28] | Briguglio E, Di Paola R, Paterniti I, et al.WY-14643,a Potent Peroxisome Proliferator Activator Receptor-alpha PPAR-alpha Agonist Ameliorates the Inflammatory Process Associated to Experimental Periodontitis[J].PPAR Res, 2010, 2010:193019- |
| [29] | Dennis Lanfear P V.PPAR-gamma agonist for treatment of bone disorders United States. Patent Application Publication Pub . No . : US 2019 / 0167660 A1. |
| [30] | Jain M R, Giri S R, Bhoi B, et al.Dual PPARalphagamma agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models[J].Liver Int, 2018, 38(6):1084-1094 |
| [31] | Smith S Y, Samadfam R, Chouinard L, et al.Effects of pioglitazone and fenofibrate co-administration on bone biomechanics and histomorphometry in ovariectomized rats[J].J Bone Miner Metab, 2015, 33(6):625-641 |
| [32] | Still K, Grabowski P, Mackie I, et al.The peroxisome proliferator activator receptor alphadelta agonists linoleic acid and bezafibrate upregulate osteoblast differentiation and induce periosteal bone formation in vivo[J].Calcif Tissue Int, 2008, 83(4):285-292 |
| [33] | Zhao X, Wang F, Zhou R, et al.PPARalphagamma antagonists reverse the ameliorative effects of osthole on hepatic lipid metabolism and inflammatory response in steatohepatitic rats[J].Inflammopharmacology, 2018, 26(2):425-433 |
| [34] | Qi Z G, Zhao X, Zhong W, et al.Osthole improves glucose and lipid metabolism via modulation of PPARalphagamma-mediated target gene expression in liver,adipose tissue,and skeletal muscle in fatty liver rats[J].Pharm Biol, 2016, 54(5):882-888 |
| [35] | Lefere S, Puengel T, Hundertmark J, et al.Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages[J].J Hepatol, 2020, 73(4):757-770 |
| [36] | Tan C K, Zhuang Y, Wahli W.Synthetic and natural Peroxisome Proliferator-Activated Receptor (PPAR) agonists as candidates for the therapy of the metabolic syndrome[J].Expert Opin Ther Targets, 2017, 21(3):333-348 |
| [37] | Zhong X, Xiu L L, Wei G H, et al.Bezafibrate enhances proliferation and differentiation of osteoblastic MC3T3-E1 cells via AMPK and eNOS activation[J].Acta Pharmacol Sin, 2011, 32(5):591-600 |
| [38] | Chan B Y, Gartland A, Wilson P J, et al.PPAR agonists modulate human osteoclast formation and activity in vitro[J].Bone, 2007, 40(1):149-159 |
| [39] | Matin A, Doddareddy M R, Gavande N, et al.The discovery of novel isoflavone pan peroxisome proliferator-activated receptor agonists[J].Bioorg Med Chem, 2013, 21(3):766-778 |
| [40] | Feng L, Luo H, Xu Z, et al.Bavachinin,as a novel natural pan-PPAR agonist,exhibits unique synergistic effects with synthetic PPAR-gamma and PPAR-alpha agonists on carbohydrate and lipid metabolism in dbdb and diet-induced obese mice[J].Diabetologia, 2016, 59(6):1276-1286 |
| [41] | Zhang T, Han W, Zhao K, et al.Psoralen accelerates bone fracture healing by activating both osteoclasts and osteoblasts[J].FASEB J, 2019, 33(4):5399-5410 |
| [42] | Kasonga A, Kruger M C, Coetzee M.Activation of PPARs Modulates Signalling Pathways and Expression of Regulatory Genes in Osteoclasts Derived from Human CD14+ Monocytes[J]. Int J Mol Sci, 2019, 20(7). |
| [43] | Djouad F, Ipseiz N, Luz-Crawford P, et al.PPARbetadelta: A master regulator of mesenchymal stem cell functions[J].Biochimie, 2017, 136:55-58 |
| [44] | Magadum A, Engel F B.PPARbeta/delta: Linking Metabolism to Regeneration[J]. Int J Mol Sci, 2018, 19(7). |
| [45] | Wan Y, Chong L W, Evans R M.PPAR-gamma regulates osteoclastogenesis in mice[J].Nat Med, 2007, 13(12):1496-1503 |
| [46] | Qiao W, Wang C, Huang W, et al.Peroxisome proliferator-activated receptor gamma plays dual roles on experimental periodontitis in rats[J].J Clin Periodontol, 2018, 45(5):514-523 |
| [47] | Di Paola R, Briguglio F, Paterniti I, et al.Emerging role of PPAR-betadelta in inflammatory process associated to experimental periodontitis[J].Mediators Inflamm, 2011, 2011:787159- |
| [48] | [参考文献] |
| [49] | Mirza A Z, Althagafi I I, Shamshad H.Role of PPAR receptor in different diseases and their ligands: Physiological importance and clinical implications[J].Eur J Med Chem, 2019, 166:502-513 |
| [50] | Capelli D, Cerchia C, Montanari R, et al.Structural basis for PPAR partial or full activation revealed by a novel ligand binding mode[J].Sci Rep, 2016, 6:34792- |
| [51] | Dubois V, Eeckhoute J, Lefebvre P, et al.Distinct but complementary contributions of PPAR isotypes to energy homeostasis[J].J Clin Invest, 2017, 127(4):1202-1214 |
| [52] | Botta M, Audano M, Sahebkar A, et al.PPAR Agonists and Metabolic Syndrome: An Established Role?[J]. Int J Mol Sci, 2018, 19(4). |
| [53] | Papatheodorou K, Banach M, Bekiari E, et al.Complications of Diabetes 2017[J].J Diabetes Res, 2018, 2018:3086167- |
| [54] | Ensrud K E, Crandall C J.Osteoporosis[J].Ann Intern Med, 2017, 167(3):C17-C32 |
| [55] | Kersten S, Desvergne B, Wahli W.Roles of PPARs in health and disease[J].Nature, 2000, 405(6785):421-424 |
| [56] | Lee H Y, Gao X, Barrasa M I, et al.PPAR-alpha and glucocorticoid receptor synergize to promote erythroid progenitor self-renewal[J].Nature, 2015, 522(7557):474-477 |
| [57] | Bougarne N, Weyers B, Desmet S J, et al.Molecular Actions of PPARalpha in Lipid Metabolism and Inflammation[J].Endocr Rev, 2018, 39(5):760-802 |
| [58] | Huang M S, Lu J, Ivanov Y, et al.Hyperlipidemia impairs osteoanabolic effects of PTH[J].J Bone Miner Res, 2008, 23(10):1672-1679 |
| [59] | Kim Y H, Jang W G, Oh S H, et al.Fenofibrate induces PPARalpha and BMP2 expression to stimulate osteoblast differentiation[J].Biochem Biophys Res Commun, 2019, 520(2):459-465 |
| [60] | Stunes A K, Westbroek I, Gustafsson B I, et al.The peroxisome proliferator-activated receptor (PPAR) alpha agonist fenofibrate maintains bone mass,while the PPAR gamma agonist pioglitazone exaggerates bone loss,in ovariectomized rats[J].BMC Endocr Disord, 2011, 11:11- |
| [61] | Mosti M P, Ericsson M, Erben R G, et al.The PPARalpha Agonist Fenofibrate Improves the Musculoskeletal Effects of Exercise in Ovariectomized Rats[J].Endocrinology, 2016, 157(10):3924-3934 |
| [62] | Pang M, de la Monte S M, Longato L, et al.PPARdelta agonist attenuates alcohol-induced hepatic insulin resistance and improves liver injury and repair[J].J Hepatol, 2009, 50(6):1192-1201 |
| [63] | Neels J G, Grimaldi P A.Physiological functions of peroxisome proliferator-activated receptor beta[J].Physiol Rev, 2014, 94(3):795-858 |
| [64] | Schug T T, Berry D C, Shaw N S, et al.Opposing effects of retinoic acid on cell growth result from alternate activation of two different nuclear receptors[J].Cell, 2007, 129(4):723-733 |
| [65] | Magadum A, Ding Y, He L, et al.Live cell screening platform identifies PPARdelta as a regulator of cardiomyocyte proliferation and cardiac repair[J].Cell Res, 2017, 27(8):1002-1019 |
| [66] | Maltarollo V G, Kronenberger T, Windshugel B, et al.Advances and Challenges in Drug Design of PPARdelta Ligands[J].Curr Drug Targets, 2018, 19(2):144-154 |
| [67] | Scholtysek C, Katzenbeisser J, Fu H, et al.PPARbetadelta governs Wnt signaling and bone turnover[J].Nat Med, 2013, 19(5):608-613 |
| [68] | Mosti M P, Stunes A K, Ericsson M, et al.Effects of the peroxisome proliferator-activated receptor (PPAR)-delta agonist GW501516 on bone and muscle in ovariectomized rats[J].Endocrinology, 2014, 155(6):2178-2189 |
| [69] | Qian G, Fan W, Ahlemeyer B, et al.Peroxisomes in Different Skeletal Cell Types during Intramembranous and Endochondral Ossification and Their Regulation during Osteoblast Differentiation by Distinct Peroxisome Proliferator-Activated Receptors[J].PLoS One, 2015, 10(12):e143439- |
| [70] | Shafi S, Gupta P, Khatik G L, et al.PPARgamma: Potential Therapeutic Target for Ailments Beyond Diabetes and its Natural Agonism[J].Curr Drug Targets, 2019, 20(12):1281-1294 |
| [71] | Wan Y.PPARgamma in bone homeostasis[J].Trends Endocrinol Metab, 2010, 21(12):722-728 |
| [72] | Brun J, Berthou F, Trajkovski M, et al.Bone Regulates Browning and Energy Metabolism Through Mature OsteoblastOsteocyte PPARgamma Expression[J].Diabetes, 2017, 66(10):2541-2554 |
| [73] | Lu W, Wang W, Wang S, et al.Rosiglitazone Promotes Bone Marrow Adipogenesis to Impair Myelopoiesis under Stress[J].PLoS One, 2016, 11(2):e149543- |
| [74] | Marciano D P, Kuruvilla D S, Boregowda S V, et al.Pharmacological repression of PPARgamma promotes osteogenesis[J].Nat Commun, 2015, 6:7443- |
| [75] | Briguglio E, Di Paola R, Paterniti I, et al.WY-14643,a Potent Peroxisome Proliferator Activator Receptor-alpha PPAR-alpha Agonist Ameliorates the Inflammatory Process Associated to Experimental Periodontitis[J].PPAR Res, 2010, 2010:193019- |
| [76] | Dennis Lanfear P V.PPAR-gamma agonist for treatment of bone disorders United States. Patent Application Publication Pub . No . : US 2019 / 0167660 A1. |
| [77] | Jain M R, Giri S R, Bhoi B, et al.Dual PPARalphagamma agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models[J].Liver Int, 2018, 38(6):1084-1094 |
| [78] | Smith S Y, Samadfam R, Chouinard L, et al.Effects of pioglitazone and fenofibrate co-administration on bone biomechanics and histomorphometry in ovariectomized rats[J].J Bone Miner Metab, 2015, 33(6):625-641 |
| [79] | Still K, Grabowski P, Mackie I, et al.The peroxisome proliferator activator receptor alphadelta agonists linoleic acid and bezafibrate upregulate osteoblast differentiation and induce periosteal bone formation in vivo[J].Calcif Tissue Int, 2008, 83(4):285-292 |
| [80] | Zhao X, Wang F, Zhou R, et al.PPARalphagamma antagonists reverse the ameliorative effects of osthole on hepatic lipid metabolism and inflammatory response in steatohepatitic rats[J].Inflammopharmacology, 2018, 26(2):425-433 |
| [81] | Qi Z G, Zhao X, Zhong W, et al.Osthole improves glucose and lipid metabolism via modulation of PPARalphagamma-mediated target gene expression in liver,adipose tissue,and skeletal muscle in fatty liver rats[J].Pharm Biol, 2016, 54(5):882-888 |
| [82] | Lefere S, Puengel T, Hundertmark J, et al.Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages[J].J Hepatol, 2020, 73(4):757-770 |
| [83] | Tan C K, Zhuang Y, Wahli W.Synthetic and natural Peroxisome Proliferator-Activated Receptor (PPAR) agonists as candidates for the therapy of the metabolic syndrome[J].Expert Opin Ther Targets, 2017, 21(3):333-348 |
| [84] | Zhong X, Xiu L L, Wei G H, et al.Bezafibrate enhances proliferation and differentiation of osteoblastic MC3T3-E1 cells via AMPK and eNOS activation[J].Acta Pharmacol Sin, 2011, 32(5):591-600 |
| [85] | Chan B Y, Gartland A, Wilson P J, et al.PPAR agonists modulate human osteoclast formation and activity in vitro[J].Bone, 2007, 40(1):149-159 |
| [86] | Matin A, Doddareddy M R, Gavande N, et al.The discovery of novel isoflavone pan peroxisome proliferator-activated receptor agonists[J].Bioorg Med Chem, 2013, 21(3):766-778 |
| [87] | Feng L, Luo H, Xu Z, et al.Bavachinin,as a novel natural pan-PPAR agonist,exhibits unique synergistic effects with synthetic PPAR-gamma and PPAR-alpha agonists on carbohydrate and lipid metabolism in dbdb and diet-induced obese mice[J].Diabetologia, 2016, 59(6):1276-1286 |
| [88] | Zhang T, Han W, Zhao K, et al.Psoralen accelerates bone fracture healing by activating both osteoclasts and osteoblasts[J].FASEB J, 2019, 33(4):5399-5410 |
| [89] | Kasonga A, Kruger M C, Coetzee M.Activation of PPARs Modulates Signalling Pathways and Expression of Regulatory Genes in Osteoclasts Derived from Human CD14+ Monocytes[J]. Int J Mol Sci, 2019, 20(7). |
| [90] | Djouad F, Ipseiz N, Luz-Crawford P, et al.PPARbetadelta: A master regulator of mesenchymal stem cell functions[J].Biochimie, 2017, 136:55-58 |
| [91] | Magadum A, Engel F B.PPARbeta/delta: Linking Metabolism to Regeneration[J]. Int J Mol Sci, 2018, 19(7). |
| [92] | Wan Y, Chong L W, Evans R M.PPAR-gamma regulates osteoclastogenesis in mice[J].Nat Med, 2007, 13(12):1496-1503 |
| [93] | Qiao W, Wang C, Huang W, et al.Peroxisome proliferator-activated receptor gamma plays dual roles on experimental periodontitis in rats[J].J Clin Periodontol, 2018, 45(5):514-523 |
| [94] | Di Paola R, Briguglio F, Paterniti I, et al.Emerging role of PPAR-betadelta in inflammatory process associated to experimental periodontitis[J].Mediators Inflamm, 2011, 2011:787159- |
| No related articles found! |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
